Treatment

SAR443579 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
This study is testing a new medicine called SAR443579 for adults and children with certain types of blood cancers that haven't responded to other treatments. It aims to find the right dose and see how well it works and if it's safe.
For: Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia
France · Netherlands